In the latest challenge to a drug maker over the pricing of its medicines, a cost-effectiveness watchdog has determined that all three cystic fibrosis drugs sold by Vertex Pharmaceuticals (VRTX) are overpriced — and by considerable amounts.
How much? Vertex would have to lower its prices from 71 percent to 77 percent in order to align costs with the benefits, according to a review by the Institute for Clinical and Economic Review.
About the Author Reprints
